• Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin, and SYMNET study group.
• Beaujon Hospital and Paris Diderot University, Clichy, France. Electronic address: philippe.ruszniewski@bjn.aphp.fr.
• Dig Liver Dis. 2016 May 1; 48 (5): 552-558.

BackgroundLanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.AimTo evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome.MethodsThis was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control.ResultsOf 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%.ConclusionsLanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

28 keywords...

hide…